The aim of this retrospective study in primary health care was to study gender differences in blood pressure levels in response to treatment of new onset hypertension. Gender difference in blood pressure control and pharmacological treatment was also recorded. A total of 334 women and 332 men aged X50 years and o80 years at baseline, with blood pressure X140 mm Hg systolic and/or X90 mm Hg were included. Men were younger, had a higher frequency of type II diabetes mellitus and a higher body mass index compared with women at baseline. There was no difference between women and men in systolic blood pressure (SBP) before or after treatment. Women however had a lower diastolic blood pressure (DBP) before and after intervention and as a result a higher pulse pressure (PP). Approximately 50% of the patients reached target blood pressure (p140/ 90 mm Hg) in both women and men. Beta blocker was the most commonly used antihypertensive treatment in both genders, whereas diuretics were predominately used in women. In conclusion; women and men reached target blood pressure to the same extent but with different antihypertensive treatment strategies. Differences at baseline in risk factor pattern may explain the finding.
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Introduction
It is well established that uncontrolled hypertension is an important cause of cardiovascular mortality and morbidity. 1 Further the benefit of treatment is undisputable. 2 Despite well established treatment recommendations (o140/90 mm Hg, and o130/80 mm Hg in patients with diabetes mellitus) it is known that a vast majority of patients with hypertension have a blood pressure that must be described as uncontrolled. 3 The question regarding gender differences in the treatment of hypertension has lately received attention. 4, 5 According to guidelines, the choice of treatment should be irrespective of gender. Rather the individual cardiovascular risk ought to determine when treatment should be started. 6 We know that systolic blood pressure (SBP) rise steeper in postmenopausal women compared with men, and data suggest that older women have a lower rate of blood pressure control and more often receive diuretics in the treatment of high blood pressure. 7 Owing to few side effects and better compliance, newer pharmacological treatments blocking the renin-angiotensin-aldosterone system are frequently used in the treatment of hypertension in primary care and there are evidence of a better cost benefit profile with these drugs. 8 Few studies have been designed to evaluate whether gender has a role in the response to treatment of new onset of hypertension. Several observational studies have established that there are differences in the choice of treatment with respect to gender but studies in clinical practice are scarce. 9 In randomized controlled trials it has been shown that time to achieve target blood pressure is important for outcome but the information concerning this in primary health care is limited. 10 We have recently found that the gender of the physician may have a role in risk factor control, but we lack information regarding how the physician chooses the pharmacological treatment in each individual and to what extent patients gender may have a role in this decision. 11 The hypothesis in our study was that there were gender differences in the outcome of treatment of hypertension. Therefore, we examined changes in blood pressure in hypertensive women and men from intervention to the point where physicians regarded blood pressure to be well controlled. We studied gender differences in reaching target blood pressure (p140/90), in time to achieve target blood pressure and also regarding the pharmacological treatments administered.
Materials and methods
Swedish Hypertension Open care retrospective study in men and Women was a retrospective study in out patients in Sweden, carried out in patients visiting primary health care centres from January to December 2003, followed up from November 2004 to April 2006. Women and men aged X50 years and o80 years at baseline, with new onset of hypertension where pharmacological treatment was considered necessary, were included in the study. The trial was performed in 89 sites, of which 61 were private practitioners and 28 were primary health care centres. The sites were mainly located in the regions of Stockholm, Gö teborg and Malmö , which are urban areas. The exclusion criteria were concomitant heart failure, myocardial infarction within the last 6 months or unstable angina pectoris, serum creatinine 4130 mmol l -1 , atrial fibrillation, ALT or AST 43 times upper limit of normal, pregnancy, body mass index 435 or secondary hypertension. Patient data from the investigator files was logged. All data were anonymous once logged. The treating physician at each site recruited the patients to the study. The first female patient and the first male patient from the investigators files being diagnosed with hypertension in one of the following pre-specified months were included, with an upper limit of 12 patients per site, six women and six men. Only one female and one male patient per month were included. Patients were included every second month from January to December 2003. If no patient could be found in the pre-determined month, the first patient in the next month could be selected. Antihypertensive treatment was to be started no later than December 2003. Blood pressure after intervention was measured following a minimum of 8 weeks and a maximum of 6 months after treatment start or after the last change in medication. The site determined when they had reached satisfying blood pressure control. Neither patients where non pharmacological treatment was sufficient to reach blood pressure goals, nor patients who did not attend follow-up visits were included in the study.
Baseline characteristics were sex, age, weight, height and body mass index. Risk factors were considered to be diabetes mellitus (clinical diagnosis), family history of cardiovascular disease (male relatives o55 years and female relatives o65 years), smoking, known coronary disease, cholesterol levels considered clinical significantly elevated by the physician, and proteinuria. The occurrence of hormone replacement therapy in women was registered. Blood pressure at baseline was a mean value of three measurements measured before the start of treatment according to the normal standard in each site. Blood pressure could be measured by either a nurse or a physician. Weight was also measured at follow up. Medication was recorded with trade name and dose in milligrams. Blood samples were collected when treatment was started.
The study was approved by the Regional Ethical Review Board in Gö teborg. The sponsor of the study, Solvay Pharma AB, had no role in the data analyses, data interpretation or writing of the report.
Statistical methods
The sample size was calculated from data in the SCOPE trial, in which a difference of 3.2 mm Hg in SBP was associated with a reduction of stroke. Thus a sample size of 1190 patients, 595 in each group (women/men) would have a 90% power to detect a difference of 3.2 mm Hg between groups for the SBP. Comparability of the groups was assessed using t-test for independent samples, or Wilcoxon's ranksum test if the normal assumption did not hold. For continuous variables w 2 -test for categorical variables was used. All statistical tests were two-sided and considered significant at Po0.05. All confidence intervals were 95%. P-values were adjusted with multiple testing for primary variables but not for secondary analyses. The proportion of women and men reaching the predefined goal of treatment (p140/90 mm Hg) were calculated using a dichotomous variable. Only subjects reaching both systolic and diastolic blood pressure goal were defined as reaching the target. Patients were not excluded from the analysis for reasons other than missing values. Patients who did not fulfill all of the inclusion criteria and patients who fulfilled at least one of the exclusion criteria were described and summarized. Tabulations and data analyses were performed using SAS software version 9.1 or newer.
Results

Baseline characteristics
A total of 666 patients at 89 sites, 332 male and 334 female patients, were included in the study. Concerning baseline characteristics some differences were found (Table 1) . The number of patients with one or more risk factors was more pronounced in men (36%) compared with women (29%). At treatment start 15% of the women used synthetic estrogens. In all 30 patients, 13 men and 17 women were violating one or several exclusion and/or inclusion criteria. Subgroup analysis of these patients showed negligible effect of blood pressure levels or proportion of patients reaching target blood pressure. Table 2 ). The decrease in the SBP in response to treatment was equal in women and men. However, women had a lower mean diastolic blood pressure (DBP) both before (men 98.6 mm Hg, women 97.1 mm Hg) and after intervention (men 83.3 mm Hg, women 81.4 mm Hg) compared with men. There was no difference in the change of DBP from before to after intervention among women or men. As a result of the lower DBP, mean pulse pressure before and after intervention was higher in females (Po0.05). There was no difference between the proportion of women and men reaching the predefined goal of treatment (p140/90 mm Hg). Fiftythree percent of the women and fifty-two percent of the men reached target blood pressure. Patients older than 65 years of age reached target blood pressure in only 38%, whereas patients younger than 65 reached target blood pressure in 59% of the cases. In patients with diabetes mellitus only 16.7% among women and 30.6% among men reached the pre-defined treatment goal (p130/80 mm Hg). The difference between genders was not significant.
Blood pressure
There was no difference in mean SBP between men and women before (men 169.8 mm Hg, women 171.9 mm Hg) or after intervention (men 141.3 mm Hg, women 141.5 mm Hg) (
Antihypertensive drugs
The average number of medications used was 2.3 in men and 2.2 in women. Beta blocker was the most commonly prescribed treatment in both women and men; more than 50% of the patients were treated with beta blockers. Diuretics were the second most common antihypertensive drug; 47.6% of the women were treated with diuretics but only 39.2% of the men. Calcium channel blockers and angiotensin-converting enzyme (ACE) inhibitors were numerically more common in men. Angiotensin II receptor blockers (ARB) were equally common in both women and men (Figure 1 ). About 39% of the patients were treated with only one antihypertensive drug and among these patients 49% reached blood pressure p140/90 mm Hg. In patients treated with two antihypertensive drugs (28%), 55% reached target blood pressure patients with three different antihypertensive drugs (18%) reached treatment goals in 59%. The time from start of treatment to the end of the study when the investigator considered that treatment goal was achieved was in mean 403 days in men and 394 days in women. 
Discussion
The aim of this retrospective study in male and female outpatients was to primarily compare treatment effect size between men and women. Both genders were equally represented in this study. SBP before and after treatment did not differ between the genders, but a significantly lower DBP in women before and after treatment resulted in a higher pulse pressure compared with men. Treatment goals were reached in more than 50 percent of the patients without any differences between genders, but less than half of the patients were prescribed more than one antihypertensive drug. b-blockers were the most commonly prescribed antihypertensive treatment in both genders while diuretics were predominantly prescribed to women. It is well-known that there are difficulties in reaching target blood pressure goals in observational studies. The reason for this is multifactorial, ranging from the physicians interest to the patients compliance. In our study, however, 50% of the patients reached target blood pressure. In studies regarding treatment of hypertension the percentage of patients reaching blood pressure goal varies between 20 and 25%. 3 An explanation of the present result can be that the study population was quite healthy with a low proportion of patients with diabetes mellitus, current smoking or established coronary disease. But it is possible that as the participating sites were not randomly chosen we included investigators interested in hypertension, which resulted in better treatment control. It is interesting that treatment goals can be reached to a higher extent in clinical practice than has been found in observational studies. In patients with type II diabetes mellitus the percentage reaching target blood pressure (p130/80 mm Hg) was low. In our study, however, the proportion of patients with type II diabetes was small and it could be wise not to draw any firm conclusions concerning this finding. An explanation for the higher pulse pressure in women in our study can be that the women were older and DBP is known to decline with age. 12 Women more often received treatment with diuretics compared with men and this finding is in line with previous observational investigations. 13 The reason for this is unclear. Diuretics are welldocumented, cheap and often well-tolerated drugs with a good antihypertensive effect.
14 In clinical practice it is well recognized that older women often present peripheral oedema, which may lead the physician to choose a diuretic as first line therapy. Nevertheless, there are important and dangerous side-effects with hyponatraemia, which older women seem to be more susceptible to. Older women have also shown an increased risk of neurological complications following rapid correction of hyponatraemia. 15 In addition, compliance is known to be low on diuretics and the tendency to induce type II diabetes is well-documented. 8, 16 In our study men more often received ACE inhibitors compared with women. Men also had a higher prevalence of diabetes mellitus at baseline and this could explain the more frequent use of ACE inhibitors. Another explanation can be the well-known fact that women display more side effects on ACE inhibitors. 17 The highest persistence has been shown in patients using ARBs. 8 In our study the use of ARBs was unusually high and it cannot be ruled out that this could have contributed to the high rate of patients reaching target blood pressure. However, more than two-thirds of the participating sites were owned by private practitioners and this could also explain the high degree of prescriptions of ARBs because primary health care centres within the regular social security system possibly were more adherent to recommendations by the Medical Products Agency in Sweden where diuretics, calcium channel blockers and ACE inhibitors are recommended as first line antihypertensive therapy. Finally, beta-blockers were found to be the most commonly used antihypertensive therapy. At the time when the study was performed this treatment regimen was in line with the current treatment recommendations in Sweden.
Half of the patients who received one antihypertensive drug did not reach target blood pressure. We know from many randomized controlled trials that combination therapy is successful. Thus it is of great concern to establish the fact that the patient is not well treated until blood pressure goal is reached, and combination of two or more antihypertensive drugs is often necessary. 18 The average time to satisfying treatment results was more than 1 year. This information is not often found in clinical trials but reflects the reality in primary health care in Sweden.
Limitations
There are some limitations of this study. The sample size of the study was intended to be 595 women and 595 men. However, this could not be achieved due to difficulties in recruiting patients. This results in an underpowered study. Furthermore, the sites were not included by random, rather the sites were recruited by interest of the physician and this could obviously influence the results of the investigation. In addition, the selection of patients cannot be considered to be completely random even if patients were identified from investigators files in prespecified months in a random process. Finally, blood pressure measurements followed the standard of the individual clinic and were not standardized with respect to the rest of the clinics included.
The results from the study highlight the possibility to reach target blood pressure to a higher extent than is usually seen in clinical practice. The physician's interest in hypertension and its treatment may have affected the accomplished blood pressure levels in this study and point out the possible impact of sincere interest among the treating physicians. Also, knowledge about better treatment regimens for patients with co-morbidity may increase the number of patients actually reaching blood pressure target. Awareness about the differences in treatment regime between women and men could affect equality in hypertensive treatment.
In conclusion, in this rather large retrospective study, in which the primary aim was to compare treatment effect size in women and men, half of the patients reached target blood pressure. Women and men reached target blood pressure to the same extent but with different antihypertensive treatment strategies. The reason for the diverse pharmacological treatment between women and men is unclear, but differences at baseline can in part explain the finding.
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